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Abstract
·AIM: To evaluate the efficacy and safety of glaucoma
drainage device Ex-PRESS誖 P-50 for combined cataract
surgery and glaucoma.
·METHODS: Patients having cataract and open angle
glaucoma or patients with open advanced glaucoma
which needed two or more antiglaucoma medications
were included. Combined cataract surgery and glaucoma
with Ex-PRESS誖 P-50 model placed under scleral flap
was performed.
·RESULTS: Out of 40 eyes of 40 patients (55% male and
45% female) completed the study during one -year
follow -up. The mean of age was 76.6 依11.02y. The
intraocular pressure (IOP) decreased significantly during
the 12-month follow-up from 23.5 mm Hg to 16.8 mm Hg
(Wilcoxon signed ranks test, <0.001). A 59.5% of
patients did not need any topical treatment, 10.8% of
them needed one active principle, 27% needed two active
principles, and 2.7% of them needed three active
principles for successful IOP control (<21 mm Hg).
·CONCLUSION: Combined surgery of phacoemulsification
with ExPRESS誖 P-50 lowers IOP from the preoperative
baseline and reduces significantly the number of
antiglaucoma active principles for IOP control after the
operation.
· KEYWORDS: ExPRESS; combined surgery; cataract
surgery; glaucoma surgery
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INTRODUCTION
C ataract and glaucoma usually affect elderly population.Both pathologies are strongly related to the aging
process and may frequently affect the same individual
patient. Besides age, this might be related to the possible role
of antiglaucoma medications in the progression of lens
opacity [1-10]. Glaucoma filtering surgery is indicated when
glaucomatous damage progresses despite the lower level of
intraocular pressure (IOP) obtained with pharmacological
treatment. It is also required when maximun
antiglaucomatous medications are insufficient to decrease
IOP to targeted levels [1-11]. When cataract surgery and
glaucoma surgery are required, these can be performed
separately or in combination. Trabeculectomy has been the
gold-standard treatment for primary open angle glaucoma
(POAG) since 1968 [1]. However, the tube-shunt operations
may be equally effective in controlling POAG [2-11]. While
full-thickness filtration procedures considerably reduced the
IOP, they were associated with early postoperative hypotony
and related side effects and became progressively less
popular. Glaucoma drainage implants, designed to shunt the
aqueous posteriorly, represent an alternative method for
lowering IOP in glaucomatous patients [2-8]. The ExPRESS®
glaucoma filtration device (Alcon, Fort Worth, Texas, USA)
is a stainless steel miniature glaucoma device, developed as
an alternative to trabeculectomy for patients with POAG.
This procedure would be theoretically more reproducible and
simple to perform as well as less traumatic to the ocular
tissue than traditional filtering surgery. Although the standard
trabeculectomy is still the most commonly used glaucoma
operation worldwide, the Ex-PRESS exhibits similar
outcomes with fewer early postoperative complications [2-5]. It
was initially inserted from the limbus into the anterior
chamber and placed underneath the conjunctiva, the currently
adopted method places it under the scleral flap to avoid
overfiltration, exposure of the Ex-PRESS, and other
complications [6-9]. This shunt procedure can be performed on
its own or in combination with cataract surgery by
phacoemulsification[2].
The combined cataract surgery by phacoemulsification and
trabeculectomy has been successfully performed [10]. This
combined procedure enables to lower the IOP and gain in
visual acuity in one surgery, with the treatment of two
Ex-PRESS implant in combined cataract surgery
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distinct disorders [10]. Combined surgery for cataract and
glaucoma is associated with less long-term IOP reduction
compared with trabeculectomy alone. Nevertheless,
combined surgery effectively lowers IOP and reduces the
long-term requirement for antiglaucoma medications without
additional complications[11]. However, the early postoperative
hypotony and related side effects, such as choroidal
detachment, athalamia and pharmacologic midriasis by
cycloplegic agents, cause slower visual recovery. The
emergence of new devices in glaucoma filtering surgery may
contribute these complications to be less frequent in
combined cataract and glaucoma surgery[12-13]. The Ex-PRESS®
glaucoma filtration device is a miniature stainless steel
glaucoma device, developed as an alternative to
trabeculectomy and to the other types of glaucoma filtering
surgery for patients with POAG. The Ex-PRESS ® R-50
device has been successfully employed to increase outflow in
glaucoma patients [2,4-5]. Some studies have shown that
phacoemulsification plus Ex-PRESS® R-50 implantation are
significantly more effective in reducing IOP and medication
use than phacoemulsification alone [6,14]. A second generation
Ex-PRESS® P-50 has recently been developed. To the best of
our knowledge, the efficacy and safety of the new Ex-PRESS®
P-50 device have only been evaluated in glaucoma filtering
surgery [15-16] but not in combined surgery. The purpose of this
study was to evaluate the mid-term efficacy and safety of the
Ex-PRESS ® P-50 implanted under scleral flap in combined
cataract and glaucoma surgery.
MATERIALS AND METHODS
This noncomparative, nonrandomised, nonmasked prospective
interventional trial was conducted to assess the efficacy and
safety of the Ex-PRESS® P-50 device combined with cataract
surgery. The enrolled patients had an open angle glaucoma or
pseudoexfoliative glaucoma and were sent to our department
for cataract surgery. This study was approved by the Ethics
Committee of the Universitary Hospital Arnau de Vilanova
(CEIC) and was conducted according to the tenets of the
Declaration of Helsinki. After information of the procedure a
written informed consent for combined Ex-PRESS ® P-50
implantation and cataract surgery was obtained from each
patient.
Materials Subjects were recruited prospectively at the
Department of Ophthalmology, Universitary Hospital Arnau
de Vilanova (Lleida, Spain). All patients underwent a
complete ophthalmic evaluation including: best corrected
visual acuity (BCVA), slit-lamp biomicroscopy, Goldmann
applanation tonometry IOP measurement, gonioscopy, dilated
fundus examination. Posteriorly, an automated perimetry
(Humphrey, Carl Zeiss, Germany) and retinal nerve fiber
layer study by optical coherence tomography (OCT) (Stratus,
Carl Zeiss, Germany) to assess the stage of the glaucoma
were performed.
The inclusion criteria were patients with cataract and
coexisting medically uncontrolled open angle glaucoma or
pseudoexfoliative glaucoma. Clinical indication for combined
cataract surgery and glaucoma filtering surgery was patients
with BCVA 臆0.3 logMAR scale and IOP > 21 mm Hg with
topical antiglaucomatous eyedrops. Patients with advanced
glaucoma with IOP betwen 17 and 22 mm Hg who needed
two or more antiglaucoma medications and had to be
operated on for cataracts were also included. Patients with
neovascular glaucoma, primary angle-closure glaucoma,
congenital or juvenile glaucoma, normal-tension glaucoma or
prior filtering surgery were excluded. The number of
preoperative and postoperative antiglaucoma active
principles was processed for statistical analysis.
Surgical Technique The surgical procedures were
performed under peribulbar anesthesia and sedation. Topical
5% povidone-iodine was applied 10min prior surgery. After a
fornix-based conjunctival flap was performed, a partial
thickness of scleral flap of one-half to two-thirds scleral
thickness was created similar to trabeculectomy. The scleral
dissection was carried forward to the clear cornea to gain
adequate exposure of the scleral spur. Cataract surgery with a
standard sutureless temporal or nasal clear corneal
phacoemulsification and posterior chamber foldable acrylic
IOL implantation was performed, prior to the Ex-PRESS ®
P-50 implantation, in order to ensure stability and deepen the
anterior chamber. After IOL is inside the bag, acetylcholine
1% was injected into the anterior chamber to constrict the
pupil. The anterior chamber was refilled with a viscoelastic
substance to maintain the anterior chamber pressure during
implantation maneuvers of the Ex-PRESS. Then, a puncture
wound by a 25 G needle was performed under the scleral flap
opening the anterior chamber for successful placement of the
implant. The Ex-PRESS® P-50 device comes preloaded on an
injector system. The injector device was rotated 90 degrees
prior to the insertion. It was finally rotated again to its final
position inside the eye. Posteriorly, the device was released
until the tip of its introducer and the appropriate planned
scleral flap provided good coverage of the Ex-PRESS. All
Ex-PRESS implants employed in the study were model P-50.
Scleral flap closure was achieved placing at least two 10-0
nylon sutures at the two posterior corners of the sclerotic
block. Only one suture was used in the triangular flaps.
Conjunctival closure was achieved using an 8-0 polyglactin
(Vicryl®) running suture. The viscoelastic was cleared at the
end of the operation.
Postoperative treatment consisted of topical application of
mixed eyedrops of tobramycin and dexamethasone 4 times a
day followed by gradual tapering after the first week over
approximately 4wk. During the first week moxifloxacin
eyedrops 3 times a day were also administered.
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Follow-up Postoperative visits were scheduled for 1, 7, 15d,
1, 3, 6 and 12mo. Every visit included BCVA, slit-lamp
biomicroscopy of the anterior segment, Goldmann
applanation tonometry, gonioscopy and fundus examination.
Additional topical antiglaucoma medications were added if
IOP was higher than 21 mm Hg. Side effects during the first
postoperative week were recorded. For analysis of the data
only preoperative values and at 24h, 7, 15d, 1, 3, 6 and 12mo
were recruited for the study. Patients with a follow-up lower
than 12mo were not included in the study. Success rate was
determined by IOP between 5 and 21 mm Hg for a year of
follow-up, with or without medication, and without requiring
further filtering surgery. Early hypotony was defined as IOP
臆5 mm Hg during the first two weeks.
Statistical Analysis Data are expressed as the mean 依SD
(minimum and maximum values). Statistical analyses were
carried out using the Statistical Package for Social Sciences
(SPSS 19.0 for Windows, SPSS Inc., Chicago, IL, USA).
Kolmogorov-Smirnov test was performed to check normal
distribution of variables in the sample. The Wilcoxon
signed-rank test was used to compare changes from baseline
IOP and to compare the number of antiglaucoma drugs used
by the patient. For stablishing if BCVA improved following
the surgical procedure we used the Student's -test for paired
data. Results were considered statistically significant when
<0.05.
RESULTS
A total of 40 eyes of 40 patients with both cataract and
glaucoma completed the study for one year. Their mean age
was 76.60依11.02y. Table 1 contains the demographic data.
BCVA improved significantly from 0.40依0.54 to 0.20依0.54
(logMAR scale) (Student's -test for paired data; <0.001),
and the IOP decreased significantly during the 12mo of
follow-up from 23.53依6.54 to 16.08依4.59 mm Hg (Wilcoxon
signed-ranks test; <0.001) (Table 2). Figure 1 illustrates
the trends in IOP changes from baseline preoperative values.
The diminution of IOP is maintained during the observation
period. Table 3 shows the successful outcomes after 12mo of
follow-up. Thus, 57.5% of patients did not need any
adjunctive topical treatment, 10% of them needed only one
active principle, 27.5% of eyes needed two active principles,
and 5% of them needed three active principles. The mean
time for adding antiglaucomatous medications when was
necessary was 2mo (range 15d-11mo). Table 4 shows the
success rate when we considered IOP 臆21 mm Hg. In
92.5% of eyes IOP was 臆21 mm Hg. After a follow-up of
12mo, 59.5% of patients remained without any additional
medication, while 40.5% needed additional topical treatment
(Table 4).
Complications in the early period included two cases of
ocular hypotony and uveal effusion (5%), which were solved
during the first two weeks. In two cases (5%) of triangular
flap, a suturolisis with argon laser was performed. Finally,
one case needed reintervention after a year of follow-up due
to uncontrolled IOP (2.5%).
DISCUSSION
The Ex-PRESS mini glaucoma shunt is a stainless steel
miniature shunt developed for using as an alternative
Table 1 Demographic description of the population of the study 
Parameters Patients 
No. of subjects 40 (40 eyes) 
Sex (M/F) 18 (45%)/22 (55%) 
Age (a) 76.60±11.02 
Race  Caucasian 
Types of glaucoma  
Primary open angle glaucoma 38 
Pseudoexfoliative glaucoma 1 
Traumatic open angle glaucoma 1 
 Table 2 IOP and BCVA after 12mo of follow-up           n=40 
Preoperative Postoperative 
Parameters 
Mean SD Mean SD 
P 
IOP 23.53 6.54 16.08 4.59 <0.001a 
BCVA 0.40 0.54 0.20 0.54 0.001b 
aWilcoxon signed-ranks test; bPaired samples statistics. 
Table 3 Successful outcomes after 12mo and needed of 
additive topical treatment after the follow-up          n (%) 
Frequency 
Treatments 
Preoperative Postoperative 
Without treatment 0 (0) 23 (57.5) 
One active principle 9 (22.5) 4 (10.0) 
Two active principles 27 (37.5) 11 (27.5) 
Three active principles 4 (10.0) 2 (5.0) 
Total 40 (100)          40 (100) 
 
Figure 1 Change from preoperative baseline IOP (mm Hg) in
eyes treated with phacoemulsification and Ex-PRESS Mean依
standard deviation.
Table 4 Success rate after 12mo of follow-up                n (%) 
Active principles With treatment Without treatment Total 
1 4 (10.8) 0 4 (10.8) 
2 10 (27) 0 10 (27) 
3 1 (2.7) 0 1 (2.7) 
Total 15 (40.5) 22 (59.5) 37 (92.5) 
Success IOP ≤21 mm Hg. 
Ex-PRESS implant in combined cataract surgery
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procedure to trabeculectomy [2,17]. The Ex-PRESS glaucoma
filtration device was designed to drain aqueous fluid from the
anterior chamber to the subconjunctival space, forming a
filtration bleb, akin to a trabeculectomy. It was currently
available in two models: R-model and P-model. The
Ex-PRESS R-model has a beveled tip, an external diameter
of 400 滋m (27-gauge), an internal lumen of 50 滋m, a total
device length of 2.96 mm and a uniform back plate. The
Ex-PRESS ® P-50 model has a decreased bevel angle, an
external diameter of 400 滋m , a total device length of
2.64 mm and a vertical channel back plate. It is available in
both a 50-滋m and 200-滋m internal lumen size [17]. The
P-model features vertical channels in the plate, designed to
enhance posterior flow of aqueous and formation of a more
diffuse posterior bleb. The devices also contain a relief port
designed to provide an alternative pathway for aqueous
should the axial lumen become occluded by iris, fibrin or
blood [16]. Four studies have published results of the
Ex-PRESS® R-50 implant combined with phacoemulsification
cataract extraction, two of them under conjuntival flap[6,14] and
the other ones under scleral flap [2,18]. Thus, Traverso [14]
included 26 eyes of 25 patients. The overall success rate (IOP
臆21 mm Hg), with or without medications, was 94.4% at
two years. Serious complications as conjunctival erosion
were reported in three cases (11.5%). The main limitation of
this study was the relatively small number of patients.
However, its strengths were the length of follow-up and
excellent IOP control. The second trial of the Ex-PRESS ®
R-50 shunt under conjunctival flap combined with cataract
extraction was implanted in 35 eyes of 35 patients who were
followed for up to 48mo[6]. Conjunctival erosion was reported
in four cases (11.4% ). Ten patients (32.7% ) remained
without medicatons after the follow-up. The study showed
that, despite a good IOP control, Ex-PRESS ® R-50
implantation under the conjunctiva was associated with a
relatively high number of complications. The authors
concluded that a refinement in the tube design and
implantation technique would increase the success rate.
Maris [2] implanted under scleral flap the Ex-PRESS ®
R-50 device combined with phacoemulsification in a
subgroup of 15 patients of a comparative series between
trabeculectomy and Ex-PRESS ® R-50 implant. Overall
surgical success was not different in eyes treated with
combined surgery compared with those treated only with the
Ex-PRESS device. No special complications for this
subgroup were reported. The limitations of this study were
the small subgroup of combined surgery and a follow-up of
10.8 months. Kanner [18] reported 231 eyes treated with
ExPRESS® R-50 alone and 114 eyes operated with ExPRESS®
R-50 filtering surgery and phacoemulsification with a
follow-up of 21.9mo. Compared with baseline values, the
IOP and number of glaucoma medications were significantly
lowered in both grops. However, the change of IOP from
baseline was lower after the ExPRESS® R-50 implant alone.
Present study is evidently the first report of mid-term
postoperative results in combined surgery with the Ex-PRESS®
P-50 device under scleral flap. Our success rate was similar
to Traverso [14] article and better than Rivier [6]
study. Kanner [18] did not observe in the combined group
of phacoemulsification and catarat with the R-50 model.
Nevertheless, the same study reported conjunctival erosion in
0.43% of cases with the Ex-PRESS ® R-50 device alone
without phacoemulsification. The most common device-
related complication described by Kanner [18] was
blockage of the lumen of the implant, which was effectively
treated with Nd: Yag laser. The causes of occlusion were the
presence of pigment or vitreous in the lumen. We did not
observe this complication. It may be because we had no
patients with any complication during the operation, such as
capsular bag failure and vitreous loss. In the first week,
Kanner [18] reported a 7.9% of hypotony cases. We
observed this complication in only 5% of cases, which is not
really significant. Two cases of our series needed suture lysis
(5%) for lowering the IOP after the procedure.
In our study the BCVA significantly increased. This
improvement is a direct benefit of cataract surgery as in
previous reports [6,14]. No high improvement of the visual acuity
occurred in our serie due to the advancedstage of the glaucoma.
Nevertheless, the additional IOP reduction associated to
cataract surgery may contribute to the maintenance of BCVA
during the 12-month follow-up. IOP significantly decreased
from preoperative baseline values in all follow-up exams.
Regarding the success rate, 57.5% of patients did not need
additional antiglaucoma medications and the percentage of
patients which reduced the number of topical medications
was also significant. This fact is in accordance with previous
studies[6,13-14,18]. If we take as success an IOP 臆21 mm Hg, we
obtained a 92.5% of success. 59.5% of them did not
need any treatment and 40.5 % of them needed topical
treatment for IOP control. Our success rate of 92.5% would
be in agreement with the success rate reported in the
literature, which is approximately 60% -100% for the
trabeculectomy [ 8 , 19-20 ] .
Although the percentage of success may be decresased after
the first year of the implantation of the Ex-PRESS ® P-50
device, similar rates have been described following
trabeculectomy [4]. Many trabeculectomies start failing in the
second year as do Ex-PRESS shunt implantations[11]. The main
risk factors for failure of the Ex-PRESS device are diabetes,
non-Caucasian race, and previous glaucoma surgery[4].
The advantage against trabeculectomy is that there is no
iridectomy and no sclerectomy during the implantation of the
Ex-PRESS device. Thus, the postoperative inflammation and
anterior chamber reaction may be similar to the
phacoemulsification alone in cases of combined surgery with
the advantage that it is possible to diminish additionally the
549
IOP. In the postoperative period the Ex-PRESS device do not
need additional treatment with cycloplegic agents. This fact
makes more rapid the visual recovery. Some of these
advantages make its use in special cases as patients with only
one useful eye[21].
The criticism to the use of Ex-PRESS is the significant
increased cost of the surgery [22]. However, recent published
studies conclude that visual recovery is more rapid with the
Ex-PRESS device than trabeculectomy [5]. Furthermore, the
IOP variation was lower during the early postoperative
period, and postoperative complications were less frequent
after Ex-PRES implantation compared with the classic
trabeculectomy. These results added to the caratact surgery
have an important advantage for a more rapid visual
recovery. As we have demonstrated in our study the
combined phacoemulsification with Ex-PRESS ® P-50 has a
few early complications, improves significantly BCVA,
reduces significantly the IOP from preoperative baseline
values and also reduces the number of antiglaucoma active
principles which are necessaries for IOP control. All of this
may be cost effective in the cases affected of cataract and
glaucoma.
The limitation of this study may be the number of cases;
nevertheless, it is similar or even higher than other studies[6,13-14].
The lack of a control group in which only cataract surgery
performed may be considered as a limitation since cataract
surgery alone has an impact in IOP control in such
population [23]. All of our patients were caucasians and, unlike
other studies [14], there was no racial influence in the
successful rate outcomes. To the best of our knowledge, this
is the first study of combined phacoemulsification with
Ex-PRESS® P-50.
In conclusion, the combined surgery of phacoemulsification
with the Ex-PRESS® P-50 model has few early postoperative
complications, improves significantly the BCVA, lowering
IOP from the preoperative baseline values and reducing the
number of antiglaucoma active principles after the operation.
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